MT. KISCO, N.Y., June 01, 2016 (GLOBE NEWSWIRE) -- ImmuDyne (OTCQB:IMMD) announced today the appointment of Messrs. Adam Lefton and Michael Levin to a newly-formed advisory board formed to explore further commercialization opportunities for the Company's proprietary oral beta-glucan products.
Adam Lefton previously served as Chief Marketing Officer for Nobilis Health Corp. (TSX:NHC) (NYSE:HLTH) (f/k/a Northstar Healthcare Inc.), an ambulatory surgical center group. Prior to Nobilis, Mr. Lefton was Vice President of Brand Strategy at Cancer Treatment Centers of America (CTCA), where he helped build one of the most successful hospital-based direct to consumer marketing programs in the United States.
Michael D. Levin has over 40 years of healthcare industry experience and expertise in business development and regulatory affairs having served as President at Bergstrom Nutrition (f/k/a Cardinal Nutrition), a leading global supplier of GRAS dietary ingredients, VP at Baxter Healthcare and an advisory board member at the dietary supplement subsidiary of Cancer Treatment Centers of America.
"We have long held the belief that our beta-glucan is an effective solution to large unmet needs in healthcare. We have appointed two highly-experienced executives to spearhead an advisory board that will be tasked with developing a strategy to address these needs with our solutions," stated Mark McLaughlin, CEO and President of ImmuDyne.
About ImmuDyne
ImmuDyne, Inc. (the “Company”) develops, manufactures and sells natural immune support products containing the Company’s proprietary yeast beta glucans, a group of beta glucans naturally occurring in the cell walls of yeast that have been shown through testing and analysis to support the immune system. The Company’s products include once a day oral intake capsules, as well as topical serums and creams for skin application. ImmuDyne also has developed a proprietary natural delivery technology with potential new market opportunities. All of ImmuDyne’s intellectual property is protected by patents and/or trade secrets. Additional information can be found on the web at www.immudyne.com.
Forward-Looking Statements
Cautionary language regarding Forward-Looking Statements Safe Harbor Act Disclaimer: Forward-looking statements in this release are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Certain statements in this press release, including projections with respect to ImmuDyne’s results of operations, may contain words such as "anticipates," "believes," "could," "estimates," "expects," "intends," "may," "projects," "plans," "targets" and other similar language and are considered forward-looking statements. These statements are based on management's current expectations, estimates, and forecasts. These forward-looking statements are subject to important assumptions, risks and uncertainties, which are difficult to predict and therefore the actual results may be materially different from those discussed.